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ABSTRACT
Background. Accurate comparisons of haemodialysis (HD)
and peritoneal dialysis (PD) survival based on observational
studies are difficult due to substantial residual confounding that
arises from imbalances between treatments. Propensity score
matching (PSM) comparisons confer additional advantages
over conventional methods of adjustment by further reducing
selection bias between treatments. We conducted a systematic
review of studies that compared mortality between in-centre
HDwith PD using a PSM-based approach.
Methods. A sensitive search strategy identified all citations in the
PubMed, Cochrane and EMBASE databases from inception
through November 2018. Pooled PD versus HD mortality hazard
ratios (HRs) and 95% confidence intervals (CIs) were estimated
through random-effects meta-analysis. A subsequent meta-
regression explored factors to account for between-study variation.
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Results. The systematic review yielded 214 citations with 17
cohort studies and 113 578 PSM incident dialysis patients.
Cohort periods spanned the period 1993–2014. The pooled
HR for PD versus HD was 1.06 (95% CI 0.99–1.14). There was
considerable variation by country, however, mortality risks
for PD versus HD remained virtually unchanged when strati-
fied by geographical region with HRs of 1.04 (95% CI 0.94–
1.15), 1.14 (95% CI 0.99–1.32) and 0.98 (0.87–1.10) for
European, Asian and American cohorts, respectively.
Subgroup meta-analyses revealed similar risks for patients
with diabetes [HR 1.09 (95% CI 0.98–1.21)] and without dia-
betes [HR 0.99 (95% CI 0.90–1.09)]. Heterogeneity was sub-
stantial (I2¼ 87%) and was largely accounted for by differen-
ces in cohort period, study type and country of origin.
Together these factors explained a substantial degree of
between-studies variance (R2¼ 90.6%).
Conclusions. This meta-analysis suggests that PD and in-
centre HD carry equivalent survival benefits. Reported differen-
ces in survival between treatments largely reflect a combination
of factors that are unrelated to clinical efficacy.
Keywords: haemodialysis, mortality, peritoneal dialysis
INTRODUCTION
Despite observed improvements in survival among patients
with end-stage kidney disease (ESKD), the overall risk of death
remains alarmingly high for many patients treated with dialysis
[1, 2]. Haemodialysis (HD) and peritoneal dialysis (PD) are
very different treatment strategies, both technically and mecha-
nistically, and the net benefit of each strategy on health is de-
pendent on the individual clinical efficacy in controlling fluid
status and correcting metabolic derangements without contrib-
uting to infection risk or cardiovascular disease. For patients
approaching ESKD, a full discussion of the potential advantages
and disadvantages of PD and HD is an essential component of
modern pre-dialysis care programmes. The optimal dialysis
modality that confers the greatest survival advantage remains
controversial in the absence of evidence from successfully com-
pleted randomized controlled trials [3, 4].
To date, comparative studies of survival between PD and in-
centre HD have yielded conflicting results and are purely based
on observational studies with no randomization of treatment.
Substantial systematic differences are found between PD and
HD and contribute to substantial selection bias, and many of
these characteristics are directly associated with mortality [5–
7]. Methodologically, these systematic differences may surpass
the ability of conventional methods to adjust for treatment dif-
ferences and prevent the design and completion of randomized
controlled clinical trials. Consequently there is a need for novel
and more robust statistical methods to allow more meaningful
comparisons [8]. The use of propensity scores, which was intro-
duced in the 1980s, has gained popularity in the last decade
(Supplementary data, Figure S1). These are probability scores
that are conditioned on treatment assignment. They are most
commonly used in matching subjects of different treatment
groups to achieve balance in the distribution of measured con-
founders, allowing direct estimation of causal treatment effects
(TEs). They have been shown to outperform conventional re-
gression methods and provide less biased estimates [9–11].
Given the residual uncertainty regarding the optimal sur-
vival strategy between HD and PD, we conducted a systematic
review and meta-analysis of studies that utilized exclusively a
propensity score matching (PSM) approach to compare mortal-
ity risks.
MATERIALS AND METHODS
Search strategy, study selection and data synthesis
The protocol of this review was registered and published
previously on PROSPERO (http://www.crd.york.ac.uk/PROS
PERO/display_record.php? ID¼CRD42014014323).
Electronic searches were conducted on the PubMed,
Cochrane and EMBASE databases from inception until 30
November 2018 using a sensitive search strategy
(Supplementary data, Table S1). Studies were included if they
met the following criteria: (i) primary objective to compare
mortality risks between PD and in-centre HD, (ii) adult patients
with incident ESKD, (iii) PSM as the primary strategy to control
for confounding and (iv) published in the English language.
Studies that employed propensity score methods other than a
matching strategy were not included. In addition, editorials, let-
ters and case reports were also excluded. Two reviewers (M.E.E.
and A.D.M.) independently screened and identified studies for
inclusion from a web-based platform [12]. In cases of disagree-
ment, a subsequent discussion took place with the resolution of
discrepancies by consensus. Data were extracted using a form
that was developed prior to article review. The following data
were extracted: year of publication, type of study, country of the
study, source of the cohort, years of cohort establishment, last
year of follow-up, variables used to derive propensity scores,
type of matching, number of matched patients and risk of death
estimates expressed as hazard ratios (HRs) or relative risks
(RRs). Information was retrieved where available on analysis by
age group, diabetes and duration on dialysis (vintage), as these
factors have previously been shown to modify the impact of
modality onmortality [13].
Quality assessment and risk of bias
Risk of bias was examined against the Newcastle–Ottawa
Scale for observational studies [14]. This scale awards studies a
star-based score that serves as a quick visual assessment tool
across three main domains: selection of study groups (up to
four stars), comparability of the groups (up to two stars) and as-
certainment of the exposure or the outcome of interest (up to
three stars). A maximum score of nine stars reflects a study
with the highest methodological quality. We also investigated
the quality of reporting on PSM methods and the appropriate-
ness of their use. This was assessed on the following domains as
proposed by Austin [15]: derivation of propensity scores in-
cluding choice of variables, reporting and handling of missing-
ness, type of matching methods and definitions, assessment of
matching adequacy from appropriate balance diagnostics and
adjustment for within-pair correlation in the final model.
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Statistical analysis
All analyses were conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. A random effects meta-analysis
model proposed by DerSimonian and Laird [16] was used to
calculate the pooled TE estimate. Robustness of outcome was
examined through influential sensitivity analysis where a series
of meta-analysis models were fitted with one study being omit-
ted at a time. This helped to explore outlier studies that could
have largely influenced the results towards a certain direction.
Between-studies heterogeneity was assessed using chi-square
with a significance level of P< 0.10 and I2 statistic with the fol-
lowing suggested thresholds: low (25–49%), moderate (50–
74%) and high (>75%). Random effects meta-regression
allowed exploration of factors accounting for between-studies
variation. This was performed through regression of the HR of
PD versus HD on potential explanatory factors after logarith-
mic transformation. Since the outcome was on the logarithmic
scale (log HR of PD versus HD), factors with a significantly pos-
itive coefficient value reflected an increase in HR in relation to
the referent factor while factors with a significantly negative
coefficient indicated a corresponding decrease in HR.
Covariates considered in the meta-regression model included
country location, cohort design (classified as retrospective or
prospective and the time period of the study. Three chronologi-
cal periods were defined as follows: historic, when the study
population was initiated on dialysis prior to 2000; middle,
where cohort recruitment was between 2000 and 2007; and re-
cent, if the cohort began dialysis after 2007. Potential publica-
tion bias was assessed by evaluating the study effect using visual
inspection of funnel plots and by conducting Egger’s regression
test. Analyses were conducted using R statistical software (R
Foundation, Vienna, Austria).
RESULTS
Search results and characteristics of included studies
The initial search identified 214 citations. After duplicate re-
moval and exclusion on title and abstract screening, 38 citations
qualified for a full text review. A further 21 studies were ex-
cluded for specific reasons, as shown in Figure 1. Following
these exclusions, a total of 17 studies, which were published
214 citations identified through
search in PubMed, Embase 
and Cochrane databases
(up to 30 November 2018)
135 citations after
removal of duplicates
135 records screened
on title and abstract
97 records excluded
38 records eligible
for full-text review
21 titles and full-text articles
excluded:
• 10 abstract-only publications
• 4 different PS methods
• 3 different populations
• 1 different langauge
• 1 duplicate cohort
• 1 cost-effectiveness study
• 1 correspondence
17 studies included in qualitative and
quantitative synthesis (meta-analysis)
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FIGURE 1: PRISMA flow diagram.
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between 2010 and 2018, contributed to the final meta-analysis.
These included 20 historical cohorts, as two studies included
>1 cohort [17, 18]. Ten studies were registry-based, three were
from multicentre cohorts and the remainder were single-centre
studies. There was wide geographical variability, with four stud-
ies reporting on European cohorts [17, 19–21], a further four
on North American patients [22–25] and nine on dialysis
patients from Asian countries. All studies included incident
patients who were initiated on dialysis over a period from 1993
to 2014, with six cohorts having patients commencing dialysis
before the year 2000 [17, 23, 26, 32, 33]. The total number of di-
alysis patients was 441715, from which a total of 114 608
patients were matched on propensity scores and contributed to
the final analysis. Table 1 describes the characteristics of in-
cluded studies. Some studies compared mortality risks in popu-
lations with specific characteristics, such as those with a
previous history of stroke [27], with systemic lupus
erythematosus [23], with adult polycystic kidney disease as the
cause of ESKD [26] and with chronic hepatitis C [33].
Meta-analysis of mortality risks between PD and in-
centre HD
The HR of death for PD versus in-centre HD varied among
PSM cohort studies. Overall, 10 studies did not find a signifi-
cant difference in mortality between PD and in-centre HD
[17–19, 21–23, 25, 26, 32, 33], 4 indicated better survival out-
come with PD [17, 18, 24, 30] and the remaining studies fav-
oured better survival with in-centre HD [20, 27–29, 31]. The
overall pooled HR of death for PD versus HD was 1.06 [95%
confidence interval (CI) 0.99–1.14], demonstrating that PD
and HD have similar survival rates. Although there was con-
siderable variation in magnitude and direction of the PD/HD
HR by country of origin, meta-analyses on studies from the
same geographical region (Europe, Asia and North
FIGURE 2: Forest plot for meta-analysis of PSM studies comparing mortality risk of PD versus in-centre HD. seTE, standard error of treat-
ment effect.
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American) showed equivalent mortality risks (Figure 2).
Subsequent influential sensitivity analyses revealed virtually
identical results (Supplementary data, Figure S2). There was a
substantial degree of heterogeneity across cohorts, (I2¼ 87%,
P< 0.001). No significant publication bias was found, as con-
firmed by the Egger’s test (Supplementary data, Figure S4).
However, a number of studies fell outside the pseudo 95%
confidence limits of the effect size, again confirming substan-
tial heterogeneity.
The multivariate metaregression analysis key factors that
contributed to this heterogeneity (Supplementary data, Table
S2). Differences in the country of origin, time period during
which cohorts were recruited and the type of study design (ret-
rospective versus prospective) explained 90.6% of between-
study variance. Further inspection revealed significant improve-
ments in the HR for PD versus HD over time when
comparisons were made across cohort periods (Supplementary
data, Figure S3).
Effect modifiers of the association between dialysis
modality and risk of death
Studies that tested for interactions and explored effect modi-
fication of selected variables on the PD/HD mortality relation-
ship are shown in Table 2. The effect of diabetes on the
relationship of dialysis modality and mortality was examined
in eight studies (10 cohorts). Analyses of four cohorts with dia-
betes revealed higher mortality for PD than for HD [25, 27, 28,
31]. In three cohort studies without diabetes, mortality risks
were significantly lower on PD than HD [17, 30]. A non-
significant effect was reported for the other three cohorts [17,
19, 29]. One study looked at the effect of diabetes control
among diabetic patients and showed better outcome for PD
FIGURE 3: Forest plots for meta-analyses of PD versus HD mortality risk by diabetes. seTE, standard error of treatment effect.
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patients in the group that had better glycaemic control [18].
Subgroup meta-analyses were conducted in six studies that
revealed the pooled HR for PD (versus HD) was 1.09 (95% CI
0.98–1.21) for diabetic patients and 0.99 (95% CI 0.90–1.09) for
non-diabetic patients (Figure 3). The interaction term for diabe-
tes and dialysis modality was non-significant.
Age exerted a significant effect in eight cohorts, with five
showing worse outcomes for PD among older patients and
three studies indicating favourable outcomes among younger
patients. Four cohorts showed no age effect. A meta-analysis
was not feasible due to differences in chosen age cut-off points
and lack of reported estimates.
Eight studies investigated the effect of dialysis vintage on
PD/HD mortality. Mortality risks were found to be similar in
the first 6–12months of dialysis initiation in five studies, with
four showing higher mortality for PD patients in the subse-
quent periods [25, 27–29] and one showing a higher risk among
HD patients [30]. One study found lower mortality with PD
than HD in the first year and similar risks thereafter [22]. Two
cohorts reported no evidence of change in mortality risks over
time [19, 32].
Risk of bias and appraisal of PSM methods
Studies included in this meta-analysis achieved high scores
on the Newcastle–Ottawa Scale ranging from eight to nine stars
(Supplementary data, Table S3). In contrast, our analysis
revealed that the quality of reporting on PSM varied consider-
ably (Supplementary data, Table S4). With the exception of one
study, all studies described the variables that were used to gen-
erate the propensity scores. The matching algorithm was clearly
stated in 10 studies (58.8%) while the strategy for replacement
during the PSM process was explicitly stated in only 3 studies
[17, 28, 30]. On evaluating the balance between matched
cohorts, most studies applied hypothesis testing and only four
(23.5%) used appropriate tests [22, 23, 25, 26]. Three studies ad-
justed for the paired nature of the matched cohort when esti-
mating HRs [22, 25, 31].
DISCUSSION
To the best of our knowledge, this is the first systematic review
and meta-analysis to examine in detail the relative survival ben-
efits of PD compared with in-centre HD based primarily on a
propensity-based matching strategy. Previous comparative
analysis and systematic reviews of PD/HD mortality were lim-
ited due to the inclusion of heterogeneous studies that failed to
adequately account for the effect of selection bias [34, 35]. In
this carefully constructed meta-analysis of PSM studies, we
found overall that the mortality risks were similar for PD and
in-centre HD and that the HRs for death remained unchanged
in several sensitivity analyses. However, our analysis did un-
cover significant mortality differences between HD and PD that
varied by region, over time and according to the study design.
Taken together, these new findings would suggest that while the
overall survival of incident patients treated with either PD or
HD is similar, reported differences in survival primarily reflect
differences in clinical practices within health systems and evolv-
ing clinical trends.
The choice of dialysis modality for patients approaching ESKD
is determined by a confluence of factors that are associated with
the patient, the physician and the prevailing healthcare system and
consequently results in fundamental differences between patients
selected for PD or HD. Many of these factors have been shown to
be independent predictors of survival and adverse outcomes [5–7,
36]. Therefore it has been postulated by many that the observed
differences in mortality between dialysis modalities is likely due to
selection bias rather than the treatment itself [37]. In order to over-
come this specific type of bias, many investigators have advocated
the use of PSM to estimate causal TEs rather than conventional re-
gression methods. PSM offers a number of advantages, which
make it more appealing than the latter. First, it allows estimation
of marginal TEs (average effect of treatment on the population), a
feature that is shared with randomized controlled trials. In con-
trast, conventional regression methods only permit estimation of
conditional effects (average effect on the individual) [38]. Second,
unlike conventional methods where the outcome is built in with
other predictors and confounding variables in the same model,
there is clear separation between the design phase and the process
of outcome estimation, again in a way that is analogous to ran-
domized experiments [39]. Third, as propensity scores are balanc-
ing scores, it is easy to examine the distribution of baseline
characteristics, including confounders, between treatment groups.
This helps to quantify the extent to which systematic differences
are eliminated. In contrast, goodness-of-fit tests are incapable of
determining the degree of overlap in the distribution of covariates
between treated and untreated groups [8, 40, 41].
This systematic review of more than 114 600 PSM patients
found no evidence to support the superiority in survival of one
modality over the other. However, quite strikingly, we did find
evidence of substantial heterogeneity in mortality risks between
PD and HD that mandated further analysis through meta-
regression. From these series of analyses, we identified a num-
ber of factors that explained a very large proportion of the
between-study variability from published studies. First, we
identified the ‘country of origin’ as one of the principal determi-
nants of dialysis modality survival. This perhaps reflects the dif-
ferences in healthcare systems among countries and
consequently differences in funding models and variability in
patterns of clinical care. It is likely that the reported disparities
in PD utilization rates across the globe as well as underlying fi-
nancial and reimbursement policies have differentially affected
the development of PD as a primary dialysis modality, which in
turn has contributed to differences in dialysis outcomes [42–
44]. Second, it is also possible that differences in modifiable
practice patterns such as vascular access type, PD catheter care
and fluid type, PD fluid type, length of dialysis as well as dialysis
adequacy influenced mortality, which have been shown to vary
internationally [45]. Third, although it might be expected that
centres with greater experience with PD therapy might experi-
ence better survival than HD, this has not been observed inter-
nationally [46, 47]. Indeed, mortality comparisons of PD and
HD from studies in East Asia have not confirmed superior
results for PD despite the relatively high uptake of PD.
Similarly, although epidemiological studies have demonstrated
racial differences in survival comparisons of dialysis modalities
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[48, 49], we did not find evidence to support effect modification
of race on mortality from either Asian or US cohort studies [22,
24–25].
The time span of 21 years (1993–2014) allowed us to investi-
gate temporal trends in patterns of survival between PD and
HD, as we postulated that some of the between-study heteroge-
neity in mortality might be accounted for by changing practice
patterns. In these series of analysis, a favourable trajectory in
PD versus HD mortality was observed in recent cohorts com-
pared with historic cohorts after accounting for the effects of
country and study type (Supplementary data, Figure S3). This
period effect may be explained by preferentially greater
improvements in PD compared with HD, as evident from pub-
lished reports from large registries [1, 2, 50, 51]. It may also re-
flect the advancements in pre-dialysis and in overall dialysis
care provision to patients over the past 2 decades [52, 53].
Examples of improved practice patterns include a shift in prac-
tice towards preserving residual renal function and peritoneal
membrane integrity, the advent of more PD biocompatible
fluids, improved dialysis adequacy and increased attention to
anaemia, mineral and nutrition parameters and vascular access
care [53]. Although several studies have identified diabetes as
an effect modifier of the PD/HD mortality relationship, we did
not observe evidence of this from our subgroup meta-analysis.
Similarly, while age and vintage appeared to have variable
effects, it was not possible to reach conclusive results due to a
lack of reported estimates.
A key objective of the meta-analysis was to explore the scien-
tific quality and reporting of PSM studies. Our investigations
uncovered a series of deficiencies in the reporting of statistical
methods, including a description on how the matched pairs
were formed. This is noteworthy, as a lack of clarity in the
methodology used prevents other researchers from replicating
these methods and assessing their appropriateness. Ten studies
explicitly described the algorithm used in the PSM analysis.
Furthermore, only three studies explicitly mentioned whether
the matching process was conducted with or without replace-
ment. This is important, as matching with replacement permits
a subject from the control group to contribute to more than one
matched set, resulting in multiple matched pairs with the same
control subject. This lack of independence needs to be taken
into account when estimating TEs [54, 55]. One of the most ap-
pealing advantages of using PSM is the ability to assess the de-
gree of balance achieved between matched samples in a
transparent fashion. However, the majority appeared not to
have done this, at least correctly. Most studies utilized signifi-
cance hypothesis testing such as t-tests to compare the distribu-
tion of covariates between matched cohorts. This practice has
been strongly discouraged for due to several reasons. First, these
tests are dependent on sample size. Therefore a non-significant
P-value that is simply due to an underpowered sample could
deceivingly indicate a balanced state. Second, while these tests
refer to a hypothetical population, balance is an intrinsic char-
acteristic of a matched sample that has no reference to any hy-
pothetical population. This makes the use of significance tests
rather irrelevant in determining the degree of established bal-
ance. Proper alternatives for balance diagnostics that are
independent of sample size are the use of standardized differen-
ces and quintile-to-quintile plots [41, 56]. Failure to adequately
assess the balance of potential confounders can bias estimates
and certainly defies the rationale behind the use of PSM.
Unlike balance diagnostics, there is no consensus on the
need to account for the paired nature of matched cohorts when
estimating TEs, and indeed more research is needed in this area
[38, 55, 57]. In our review, only three studies addressed this
point and adjusted the results for within-pair correlation [22,
25, 31]. These deficiencies in reporting and applying PSM
methods are similar to those reported in previous reviews that
have appraised PSM studies [15, 58–60]. This underscores the
need for greater efforts in raising awareness among nephrology
researchers and the wider scientific community.
This meta-analysis is not without limitations. Despite advan-
ces in the design and analysis of PSM subjects, it is important to
emphasize the evidence derived from PSM studies is still infe-
rior to that derived from randomized trials. Estimated propen-
sity scores are dependent on the availability and quality of
captured data. Studies usually lack variables that indicate the se-
verity of comorbid diseases, social circumstances such as family
support, frailty indicators and perhaps other important factors
that could have influenced the choice of modality and out-
comes. Also, as many included studies were registry-based, a
degree of inherent inaccuracies in coding and record complete-
ness would be expected. Therefore bias arising from unmeas-
ured confounders cannot be eliminated. It is noteworthy that in
spite of its advantages, there is not complete consensus on the
superiority of PSM versus conventional regression methods
and caution must be exercised upon implementation [40, 61].
Finally, the quality of reporting on PSMmay have been affected
by editing and word limit restrictions, as researchers may have
presented more information initially. These points should be
weighed against the rigorous systematic approach of this study,
the novel focus on mitigating selection bias through achieving
methodological uniformity, the inclusion of modern cohorts
from various geographical areas, as well as attempts to improve
the quality of performing and reporting on PSMmethods.
In conclusion, evidence derived from PSM-based compari-
sons of PD and HD indicates that PD and in-centre HD carry
similar survival rates. Differences do exist among subgroups
and these depend mainly on the country of origin and the pe-
riod during which a cohort commenced dialysis. While the
quality of reporting and conduct of PSM methods needs to im-
prove in clinical research, they remain a very useful tool in com-
paring treatment strategies and in assessing causality where
randomized clinical trials have proven difficult to implement.
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